Biological therapies of inflammatory bowel disease

Immunotherapy

Volumn 2, Issue 5, 2010, Pages 727-742

  Bai, Aiping ^a,b   Peng, Zhikang ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b NANCHANG UNIVERSITY   (China)

Author keywords

biological therapy; clinical trial; Crohns disease; immunotherapy; inflammatory bowel disease; monoclonal antibody; ulcerativecolitis

Indexed keywords

ABT 874; ADALIMUMAB; ALICAFORSEN; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CH5D12; CURCUMIN; DACLIZUMAB; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; DORAMAPIMOD; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 23; MERCAPTOPURINE; MESALAZINE; MONOCLONAL ANTIBODY; NATALIZUMAB; PLACEBO; RECOMBINANT EPIDERMAL GROWTH FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GROWTH HORMONE; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; ROSIGLITAZONE; UNCLASSIFIED DRUG; USTEKINUMAB; VEDOLIZUMAB; VISILIZUMAB;

ABSENCE OF SIDE EFFECTS; ADAPTIVE IMMUNITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL TRIAL; CROHN DISEASE; DOWN REGULATION; DRUG HALF LIFE; DRUG TARGETING; EDEMA; HELMINTH; HOSPITALIZATION; HUMAN; INNATE IMMUNITY; LACTOCOCCUS LACTIS; LEUKOCYTE MIGRATION; MORBIDITY; OOCYTE; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; T LYMPHOCYTE ACTIVATION; TRICHIURIS SUIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DRUG APPROVAL; HOSPITALIZATION; HUMANS; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASES; QUALITY OF LIFE; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 77957556165     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.51     Document Type: Review

References (129)

1. Korzenik JR, Podolsky DK: Evolving knowledge and therapy of inflammatory bowel disease. Nat. Rev. Drug Discov. 5(3), 197-209 (2006).
2. Loftus EV Jr: Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126(6), 1504-1517 (2004).
3. Kappelman MD, Rifas-Shiman SL, Porter CQ et al.: Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 135(6), 1907-1913 (2008).
4. Bernstein CN, Wajda A, Svenson LW et al.: The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am. J. Gastroenterol. 101(7), 1559-1568 (2006).
5. Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 448(7152), 427-434 (2007).
6. Kamada N, Hisamatsu T, Okamoto S et al.: Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. J. Immunol. 175(10), 6900-6908 (2005).
7. Bai AP, Ouyang Q: Probiotics and inflammatory bowel diseases. Postgrad. Med. J. 82(968), 376-382 (2006).
8. Ahern PP, Izcue A, Maloy KJ et al.: The interleukin-23 axis in intestinal inflammation. Immunol. Rev. 226, 147-159 (2008).
9. Kobayashi T, Okamoto S, Hisamatsu T et al.: IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 57(12), 1682-1689 (2008).
10. Fujino S, Andoh A, Bamba S et al.: Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52(1), 65-70 (2003). (Pubitemid 36020767)
11. Wittchen ES: Endothelial signaling in paracellular and transcellular leukocyte transmigration. Front. Biosci. 14, 2522-2545 (2009).
12. Mahida YR: The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm. Bowel Dis. 6(1), 21-33 (2000).
13. Ogata H, Hibi T: Cytokine and anticytokine therapies for inflammatory bowel disease. Curr. Pharm. Des. 9(14), 1107-1113 (2003).
14. Mannon PJ, Fuss IJ, Mayer L et al.: Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351(20), 2069-2079 (2004).
15. Andou A, Hisamatsu T, Okamoto S et al.: Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages. Gastroenterology 136(2), 564-574 e2 (2009).
16. Kamada N, Hisamatsu T, Okamoto S et al.: Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-γ axis. J. Clin. Invest. 118(6), 2269-2280 (2008).
17. Mucida D, Park Y, Kim G et al.: Reciprocal Th17 and regulatory T cell differentiation mediated by retinoic acid. Science 317(5835), 256-260 (2007).
18. Sandborn WJ: Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology 135(5), 1442-1447 (2008).
19. Katz S: Update in medical therapy of ulcerative colitis: a practical approach. J. Clin. Gastroenterol. 34(4), 397-407 (2002).
20. Papadakis KA, Targan SR: Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu. Rev. Med. 51, 289-298 (2000).
21. Wang J, Fu YX: Tumor necrosis factor family members and inflammatory bowel disease. Immunol. Rev. 204, 144-155 (2005).
22. Rutgeerts P, Van Assche G, Vermeire S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126(6), 1593-1610 (2004). (Pubitemid 38649876)
23. Rutgeerts P, Sandborn WJ, Feagan BG et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462-2476 (2005). □ First recorded use of infliximab for ulcerative colitis patients. (Pubitemid 41770166)
24. D'Haens G, Daperno M: Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr. Gastroenterol. Rep. 8(6), 506-512 (2006).
25. Baert FJ, D'Haens GR, Peeters M et al.: Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116(1), 22-28 (1999).
26. Targan SR, Hanauer SB, van Deventer SJ et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 study group. N. Engl. J. Med. 337(15), 1029-1035 (1997). □ First recorded use of infliximab for Crohn's disease patients.
27. Hanauer SB, Feagan BG, Lichtenstein GR et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317), 1541-1549 (2002). □ A Crohn's disease Clinical Trial Evaluating Infliximab in a New Long term Treatment regimen (ACCENT) I study of infliximab for Crohn's disease maintenance treatment.
28. Sandborn WJ, Rutgeerts P, Feagan BG et al.: Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 137(4), 1250-1260; quiz 1520 (2009).
29. Sands BE, Anderson FH, Bernstein CN et al.: Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 350(9), 876-885 (2004). □Infliximab maintenance therapy for fistulizing Crohn's disease.
30. Sands BE, Blank MA, Patel K et al.: Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin. Gastroenterol. Hepatol. 2(10), 912-920 (2004).
31. Cassinotti A, Ardizzone S, Porro GB: Adalimumab for the treatment of Crohn's disease. Biologics 2(4), 763-777 (2008).
32. Devlin SM, Panaccione R: Adalimumab for the treatment of Crohn's disease. Expert Opin. Biol. Ther. 8(7), 1011-1019 (2008).
33. Papadakis KA: Crohn's disease: Adalimumab improves quality of life. Nat. Rev. Gastroenterol. Hepatol. 6(4), 200-201 (2009).
34. Hinojosa J, Gomollon F, Garcia S et al.: Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment. Pharmacol. Ther. 25(4), 409-418 (2007).
35. Feagan BG, Panaccione R, Sandborn WJ et al.: Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 135(5), 1493-1499 (2008).
36. Kaushik VV, Moots RJ: CDP-870 (certolizumab) in rheumatoid arthritis. Expert Opin. Biol. Ther. 5(4), 601-606 (2005).
37. Patel VK, Ghosh S: Certolizumab pegol in Crohn's disease. Drugs Today (Barc.) 44(11), 837-844 (2008).
38. Sisson G, Harris A: Certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 130(1), 285-286; author reply 286 (2006).
39. Blick SK, Curran MP: Certolizumab pegol: in Crohn's disease. BioDrugs 21(3), 195-201; discussion 202-193 (2007).
40. Schreiber S, Rutgeerts P, Fedorak RN et al.: A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129(3), 807-818 (2005).
41. Sandborn WJ, Feagan BG, Stoinov S et al.: Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357(3), 228-238 (2007).
42. Zhang Z, Hinrichs DJ, Lu H et al.: After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease? Int. Immunopharmacol. 7(4), 409-416 (2007).
43. Gately MK, Renzetti LM, Magram J et al.: The interleukin-12/interleukin- 12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16, 495-521 (1998).
44. Peluso I, Pallone F, Monteleone G: Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World J. Gastroenterol. 12(35), 5606-5610 (2006).
45. Neurath MF, Fuss I, Kelsall BL et al.: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182(5), 1281-1290 (1995).
46. Maloy KJ: The interleukin-23/interleukin-17 axis in intestinal inflammation. J. Intern. Med. 263(6), 584-590 (2008).
47. Mudter J, Neurath MF: Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm. Bowel Dis. 13(8), 1016-1023 (2007).
48. Elliott M, Benson J, Blank M et al.: Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann. NY Acad. Sci. 1182, 97-110 (2009).
49. Sandborn WJ, Feagan BG, Fedorak RN et al.: A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135(4), 1130-1141 (2008).
50. Neuman MG: Immune dysfunction in inflammatory bowel disease. Transl. Res. 149(4), 173-186 (2007).
51. Brun V, Bastian H, Neveu V et al.: Clinical grade production of IL-10 producing regulatory Tr1 lymphocytes for cell therapy of chronic inflammatory diseases. Int. Immunop harmacol. 9(5), 609-613 (2009).
52. Braat H, Rottiers P, Hommes DW et al.: A Phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 4(6), 754-759 (2006).
53. Colombel JF, Rutgeerts P, Malchow H et al.: Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 49(1), 42-46 (2001).
54. Du X, Williams DA: Interleukin-11: review of molecular, cell biology, and clinical use. Blood 89(11), 3897-3908 (1997).
55. Grosfeld JL, Du X, Williams DA: Interleukin-11: its biology and prospects for clinical use. JPEN J. Parenter. Enteral Nutr. 23 (5 Suppl.), S67-S69 (1999).
56. Pfeiffer CJ, Sato S, Qiu BS et al.: Cellular pathology of experimental colitis induced by trinitrobenzenesulphonic acid (TNBS): protective effects of recombinant human interleukin-11. Inflammopharmacology 5(4), 363-381 (1997).
57. Sands BE, Bank S, Sninsky CA et al.: Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 117(1), 58-64 (1999).
58. Muller WA: Mechanisms of transendothelial migration of leukocytes. Circ. Res. 105(3), 223-230 (2009). □ Evidence of leukocyte migration blockade for inflammation inhibition.
59. Golias C, Tsoutsi E, Matziridis A et al.: Leukocyte and endothelial cell adhesion molecules in inflammation focusing on inflammatory heart disease. In vivo 21(5), 757-769 (2007).
60. Targan SR, Feagan BG, Fedorak RN et al.: Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 132(5), 1672-1683 (2007).
61. Sandborn WJ, Colombel JF, Enns R et al.: Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353(18), 1912-1925 (2005).
62. Van Assche G, Van Ranst M, Sciot R et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353(4), 362-368 (2005).
63. Yousry TA, Major EO, Ryschkewitsch C et al.: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354(9), 924-933 (2006).
64. Jones PT, Dear PH, Foote J et al.: Replacing the complementarity- determining regions in a human antibody with those from a mouse. Nature 321(6069), 522-525 (1986).
65. Feagan BG, Greenberg GR, Wild G et al.: Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N Engl. J. Med. 352(24), 2499-2507 (2005).
66. Simmons D, Makgoba MW, Seed B: ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM. Nature 331(6157), 624-627 (1988).
67. Vainer B: Intercellular adhesion molecule-1 (ICAM-1) in ulcerative colitis: presence, visualization, and significance. Inflamm. Res. 54(8), 313-327 (2005).
68. Migita H, Satozawa N, Lin JH et al.: RORa 1 and RORα4 suppress TNF-α-induced VCAM-1 and ICAM-1 expression in human endothelial cells. FEBS Lett. 557(1-3), 269-274 (2004).
69. Jones SC, Banks RE, Haidar A et al.: Adhesion molecules in inflammatory bowel disease. Gut 36(5), 724-730 (1995).
70. Yacyshyn BR, Barish C, Goff J et al.: Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment. Pharmacol. Ther. 16(10), 1761-1770 (2002).
71. Yacyshyn B, Chey WY, Wedel MK et al.: A randomized, double-masked, placebocontrolled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin. Gastroenterol. Hepatol. 5(2), 215-220 (2007).
72. Reichardt P, Dornbach B, Gunzer M: APC, T cells, and the immune synapse. Curr. Top. Microbiol. Immunol. 340, 229-249).
73. Reichardt P, Gunzer M: The biophysics of T lymphocyte activation in vitro and in vivo. Results Probl. Cell Differ. 43, 199-218 (2006).
74. Sharpe AH, Freeman GJ: The B7-CD28 superfamily. Nat. Rev. Immunol. 2(2), 116-126 (2002).
75. Apostolopoulos V, Lazoura E, Yu M: MHC and MHC-like molecules: structural perspectives on the design of molecular vaccines. Adv. Exp. Med. Biol. 640, 252-267 (2008).
76. Silver PB, Hathcock KS, Chan CC et al.: Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J. Immunol. 165(9), 5041-5047 (2000).
77. Appleman LJ, Boussiotis VA: T cell anergy and costimulation. Immunol. Rev. 192, 161-180 (2003).
78. Cole MS, Stellrecht KE, Shi JD et al.: HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation 68(4), 563-571 (1999).
79. Chau LA, Tso JY, Melrose J et al.: HuM291 (Nuvion), a humanized Fc receptor-nonbinding antibody against CD3, anergizes peripheral blood T cells as partial agonist of the T cell receptor. Transplantation 71(7), 941-950 (2001).
80. Plevy S, Salzberg B, Van Assche G et al.: A Phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 133(5), 1414-1422 (2007).
81. Baumgart DC, Targan SR, Dignass AU et al.: Prospective randomized open-label multicenter Phase I/II dose escalation trial of visilizumab (HuM291) in severe steroidrefractory ulcerative colitis. Inflamm. Bowel Dis. 16(4), 620-629 (2009).
82. Baumgart DC, Lowder JN, Targan SR et al.: Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am. J. Gastroenterol. 104(4), 868-876 (2009).
83. Elgueta R, Benson MJ, De Vries VC et al.: Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229(1), 152-172 (2009).
84. Boon L, Laman JD, Ortiz-Buijsse A et al.: Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys. Toxicology 174(1), 53-65 (2002).
85. Kasran A, Boon L, Wortel CH et al.: Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment. Pharmacol. Ther. 22(2), 111-122 (2005).
86. Nelson BH, Willerford DM: Biology of the interleukin-2 receptor. Adv. Immunol. 70, 1-81 (1998).
87. Morris JC, Waldmann TA: Advances in interleukin 2 receptor targeted treatment. Ann. Rheum. Dis. 59 (Suppl. 1), I109-I114 (2000).
88. Van Assche G, Sandborn WJ, Feagan BG et al.: Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 55(11), 1568-1574 (2006).
89. Inoue Y, Copeland EM, Souba WW: Growth hormone enhances amino acid uptake by the human small intestine. Ann. Surg. 219(6), 715-722; discussion 722-714 (1994).
90. Lo HC, Ney DM: GH and IGF-I differentially increase protein synthesis in skeletal muscle and jejunum of parenterally fed rats. Am. J. Physiol. 271 (5 Pt 1), E872-E878 (1996).
91. Slonim AE, Bulone L, Damore MB et al.: A preliminary study of growth hormone therapy for Crohn's disease. N. Engl. J. Med. 342(22), 1633-1637 (2000).
92. Armitage JO: Emerging applications of recombinant human granulocytemacrophage colony-stimulating factor. Blood 92(12), 4491-4508 (1998).
93. Sainathan SK, Hanna EM, Gong Q et al.: Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis. Inflamm. Bowel Dis. 14(1), 88-99 (2008).
94. Korzenik JR, Dieckgraefe BK, Valentine JF et al.: Sargramostim for active Crohn's disease. N. Engl. J. Med. 352(21), 2193-2201 (2005).
95. Takazoe M, Matsui T, Motoya S et al.: Sargramostim in patients with Crohn's disease: results of a Phase 1-2 study. J. Gastroenterol. 44(6), 535-543 (2009).
96. Bu HF, Zuo XL, Wang X et al.: Milk fat globule-EGF factor 8/lactadherin plays a crucial role in maintenance and repair of murine intestinal epithelium. J. Clin. Invest. 117(12), 3673-3683 (2007).
97. Berlanga J, Prats P, Remirez D et al.: Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage. Am. J. Pathol. 161(2), 373-379 (2002).
98. Procaccino F, Reinshagen M, Hoffmann P et al.: Protective effect of epidermal growth factor in an experimental model of colitis in rats. Gastroenterology 107(1), 12-17 (1994).
99. Sinha A, Nightingale J, West KP et al.: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl. J. Med. 349(4), 350-357 (2003).
100. Waetzig GH, Seegert D, Rosenstiel P et al.: p38 mitogen-activated protein kinase is activated and linked to TNF-α signaling in inflammatory bowel disease. J. Immunol. 168(10), 5342-5351 (2002).
101. Hommes DW, Peppelenbosch MP, van Deventer SJ: Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 52(1), 144-151 (2003).
102. Pargellis C, Tong L, Churchill L et al.: Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9(4), 268-272 (2002).
103. Schreiber S, Feagan B, D'Haens G et al.: Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol Hepatol. 4(3), 325-334 (2006).
104. Bourreille A, Doubremelle M, De La Bletiere DR et al.: RDP58, a novel immunomodulatory peptide with antiinflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn disease. Scand. J. Gastroenterol 38(5), 526-532 (2003).
105. Travis S, Yap LM, Hawkey C et al.: RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm. Bowel Dis. 11(8), 713-719 (2005).
106. Aggarwal BB, Sung B: Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol. Sci. 30(2), 85-94 (2009).
107. Atreya I, Atreya R, Neurath MF: NF-κB in inflammatory bowel disease. J. Intern. Med. 263(6), 591-596 (2008).
108. Sugimoto K, Hanai H, Tozawa K et al.: Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 123(6), 1912-1922 (2002).
109. Hanai H, Iida T, Takeuchi K et al.: Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, doubleblind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 4(12), 1502-1506 (2006). □ Novel potential treatment of herb extract for inflammatory bowel disease patients.
110. Mangelsdorf DJ, Thummel C, Beato M et al.: The nuclear receptor superfamily: the second decade. Cell 83(6), 835-839 (1995).
111. Su CG, Wen X, Bailey ST et al.: A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J. Clin. Invest. 104(4), 383-389 (1999).
112. Dubuquoy L, Rousseaux C, Thuru X et al.: PPARγ as a new therapeutic target in inflammatory bowel diseases. Gut 55(9), 1341-1349 (2006).
113. Sanchez-Hidalgo M, Martin AR, Villegas I et al.: Rosiglitazone, an agonist of peroxisome proliferator-activated receptor γ, reduces chronic colonic inflammation in rats. Biochem. Pharmacol. 69(12), 1733-1744 (2005).
114. Lytle C, Tod TJ, Vo KT et al.: The peroxisome proliferator-activated receptor-γ ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 defciency. Inflamm. Bowel Dis. 11(3), 231-243 (2005).
115. Lewis JD, Lichtenstein GR, Deren JJ et al.: Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 134(3), 688-695 (2008). □ Novel potential treatment of chemical compound for inflammatory bowel disease patients.
116. Tyndall A, Gratwohl A: Adult stem cell transplantation in autoimmune disease. Curr. Opin. Hematol. 16(4), 285-291 (2009).
117. Burt RK, Traynor A, Oyama Y et al.: High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood 101(5), 2064-2066 (2003).
118. Oyama Y, Craig RM, Traynor AE et al.: Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 128(3), 552-563 (2005).
119. + cell selection in refractory Crohn's disease. Gut 57(2), 211-217 (2008).
120. Weinstock JV: Helminths and mucosal immune modulation. Ann. NY Acad. Sci. 1072, 356-364 (2006).
121. Summers RW, Elliott DE, Urban JF Jr et al.: Trichuris suis therapy in Crohn's disease. Gut 54(1), 87-90 (2005).
122. Summers RW, Elliott DE, Urban JF Jr et al.: Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 128(4), 825-832 (2005).
123. Owczarek D, Cibor D, Szczepanek M et al.: Biological therapy of inflammatory bowel disease. Pol. Arch. Med. Wewn. 119(1-2), 84-88 (2009).
124. Sandborn WJ: New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev. Gastroenterol. Disord. 5(1), 10-18 (2005).
125. Baert F, De Vos M, Louis E et al.: Immunogenicity of infliximab: how to handle the problem? Acta Gastroenterol. Belg. 70(2), 163-170 (2007).
126. Rutgeerts P, Vermeire S, Van Assche G: Biological therapies for infammatory bowel diseases. Gastroenterology 136(4), 1182-1197 (2009).
127. Yamamoto-Furusho JK: Innovative therapeutics for inflammatory bowel disease. World J. Gastroenterol. 13(13), 1893-1896 (2007).
128. Noomen CG, Hommes DW, Fidder HH: Update on genetics in inflammatory disease. Best Pract. Res. Clin. Gastroenterol. 23(2), 233-243 (2009).
129. Mayer L: Evolving paradigms in the pathogenesis of IBD. J. Gastroenterol. 45(1), 9-16 (2010).